Saharsh Davuluri Appointed CEO & MD of Neuland Laboratories to Lead CDMO Expansion
Hyderabad, India, April 1, 2026 – Neuland Laboratories [NLL] (NSE: NEULANDLAB; BSE:524558), a global contract development and manufacturing organization (CDMO) specializing in complex APIs, announced a leadership change today. Saharsh Davuluri has assumed the role of Chief Executive Officer and Managing Director, effective immediately, as the company enters its next phase of CDMO growth.Saharsh Davuluri, who has been with the company for over 18 years, will focus on positioning Neuland as a leading global API process development and commercial manufacturing specialist. The company has tripled its contract services revenues during the last 3 years, driven by a growing reputation for scaling complex APIs and peptides.
Saharsh succeeds Sucheth Davuluri, who will now assume the role of Executive Vice Chairman of the Company.
“It’s an incredibly exciting time for the CDMO sector, and for Neuland in particular,” commented Saharsh Davuluri. “We have already committed to a four-phase expansion of commercial peptide capacity and are doubling our process development capabilities.”
Neuland Laboratories operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility, with 1218 KL of installed capacity and more than 20 commercial contracts across APIs and intermediates.
The company anticipates securing several more commercial NCE contracts, including peptides, over the next one to two years, pending customer approvals.
About Neuland Laboratories Limited
Neuland Laboratories Limited [Neuland] is a specialist API CDMO partner for big pharma and biotech, delivering process development and commercial supply services for complex molecules and New Chemical Entities. Serving clients in over 80 countries, Neuland operates three US FDA and EU GMP-compliant facilities in India, with a combined reactor capacity of approximately 1218kL. The CDMO has invested in a new commercial-scale peptide facility and is opening a dedicated R&D process development center in Hyderabad.Neuland is listed on the NSE (NEULANDLAB) and BSE (524558) in India. The company has filed over 1000 DMFs globally and offers more than 100 APIs across multiple therapeutic areas.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.